Contributions
Abstract: P1920
Type: Poster
Abstract Category: Late breaking news
Studying specific metabolomic pathways in Multiple Sclerosis (MS) patients can provide valuable clinical information to monitor the disease progression and form therapeutic protocols.
The authors attempted to quantify low molecular weight potential biomarkers for MS progress monitoring, by developing and validating a novel fast and sensitive analytical method in patients' serum.
Pre-treatment sera were obtained from 30 Relapse Remit MS patients (RRMS) (18 females-12 males) during a clinical relapse. Serum samples were also collected from 20 patients with Clinical Isolated syndrome (CIS) (11 females-9 males) and 20 healthy individuals (13 females-7 males) age and gender matched. Disease duration, relapse rate (rr for RRMS group), number of Gadolinium enhanced lesions (GdE+) and EDSS score were recorded for each MS patient. High performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) was applied for the simultaneous detection and quantification of the following suspected biomarkers: tryptophan and serotonin
Tryptophan was significantly reduced in RRMS group (F(2,67)=6,225, p=0.003) when compared with the control group. Serotonin was significantly elevated in the RRMS group (F(2,67)=4.963, p=0.010) when compared with the control group. In addition, tryptophan was correlated with disease duration in RRMS participants (r=-0,71, p=0.001) and serotonin was correlated with relapse rate (r=0,467, p=0.001) and GdE+ lesions (r=0,460, p=0.001)
Our results agree with the already established knowledge regarding low tryptophan serum concentration in Th1 autoimmune diseases and high serotonin serum concentration in Th2 diseases. The importance of the correlation of specific metabolomic signatures with certain clinical MS profiles can provide valuable information regarding the progress of the disease and the dominant pathophysiological mechanism (Th1 vs Th2). This is a preliminary report of an ongoing research project regarding the screening and quantification of potential MS biomarkers.
Disclosure: The authors have nothing to disclose
Abstract: P1920
Type: Poster
Abstract Category: Late breaking news
Studying specific metabolomic pathways in Multiple Sclerosis (MS) patients can provide valuable clinical information to monitor the disease progression and form therapeutic protocols.
The authors attempted to quantify low molecular weight potential biomarkers for MS progress monitoring, by developing and validating a novel fast and sensitive analytical method in patients' serum.
Pre-treatment sera were obtained from 30 Relapse Remit MS patients (RRMS) (18 females-12 males) during a clinical relapse. Serum samples were also collected from 20 patients with Clinical Isolated syndrome (CIS) (11 females-9 males) and 20 healthy individuals (13 females-7 males) age and gender matched. Disease duration, relapse rate (rr for RRMS group), number of Gadolinium enhanced lesions (GdE+) and EDSS score were recorded for each MS patient. High performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) was applied for the simultaneous detection and quantification of the following suspected biomarkers: tryptophan and serotonin
Tryptophan was significantly reduced in RRMS group (F(2,67)=6,225, p=0.003) when compared with the control group. Serotonin was significantly elevated in the RRMS group (F(2,67)=4.963, p=0.010) when compared with the control group. In addition, tryptophan was correlated with disease duration in RRMS participants (r=-0,71, p=0.001) and serotonin was correlated with relapse rate (r=0,467, p=0.001) and GdE+ lesions (r=0,460, p=0.001)
Our results agree with the already established knowledge regarding low tryptophan serum concentration in Th1 autoimmune diseases and high serotonin serum concentration in Th2 diseases. The importance of the correlation of specific metabolomic signatures with certain clinical MS profiles can provide valuable information regarding the progress of the disease and the dominant pathophysiological mechanism (Th1 vs Th2). This is a preliminary report of an ongoing research project regarding the screening and quantification of potential MS biomarkers.
Disclosure: The authors have nothing to disclose